Comments to FDA: Developing Nicotine Replacement Therapy Drug Products

Share page:
Docket Number:
FDA-2019-D-0297

CHPA welcomes the opportunity to comment on the draft guidance on indications for nicotine replacement therapies (NRT).

Related Posts

CHPA Statement on Valisure Citizen Petition